Simulations Plus

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Simulations Plus reports Q1 revenue decline, eyes global expansion

Simulations Plus (SLP) navigated Q1 challenges with a focus on innovation, growth, and shareholder value.
Balancing revenue streams and exploring global opportunities position the company for future success.
Commitment to science, R&D, and market expansion underscores strategic vision and adaptability.
Positive outlook for future quarters driven by achievements, market traction, and evolving strategies.

Simulations Plus reports solid Q2 earnings, eyes growth opportunities

Simulations Plus delivered a strong quarter with revenue and net income growth.
The company's focus on collaborations and AI technologies bodes well for future growth.
Challenges in certain software products and economic impacts on sales cycles noted.
Opportunities in agrochemicals, biosimilars, and inorganic growth avenues are being pursued.

Simulations Plus (SLP) reports strong Q3 earnings and expands into oncology with Immunetrics acquisition

Simulations Plus (SLP) delivered a robust performance in Q3 2023, driven by revenue growth, strategic acquisitions, and operational initiatives.
While facing challenges such as renewal rate fluctuations, SLP remains well-positioned to capitalize on opportunities for growth and expansion.
Guidance for fiscal 2023, strong backlog visibility, and the Immunetrics acquisition underscore SLP's positive trajectory and potential for sustained success.

Simulations Plus (SLP) posts strong Q4 results, eyes biosimulation growth

Simulations Plus (SLP) delivered a solid performance in Q4 2023, showcasing revenue growth, strong margins, and notable achievements. While facing challenges from market conditions and nonrenewals, the company is optimistic about growth opportunities in biosimulation and revenue contributions from the Immunetrics acquisition.

Simulations Plus (SLP) reports stellar Q1 results and eyes growth

Simulations Plus (SLP) demonstrated robust performance across key segments, with strong revenue growth and profitability metrics.
While facing challenges like varied client budgets and revenue declines in certain units, the company is well-positioned to capitalize on growth opportunities.
With a focus on customer loyalty, operational efficiency, and strategic investments, Simulations Plus is poised for continued success in the market.

Simulations Plus (SLP) reports strong Q2 growth and outlook

Simulations Plus (SLP) demonstrated robust growth in Q2 2024
Strong performance in both Software and Services segments
Positive market outlook and strategic positioning for future growth
Focused on meeting fiscal 2024 guidance targets

Simulations Plus Reports Strong Q3, Eyes Growth Initiatives

Simulations Plus delivered a strong performance in Q3 2024, driven by growth in both software and services. The launch of new software and the acquisition of Pro-ficiency highlight strategic moves to enhance offerings and market position. However, challenges in gross margin and client spending patterns could impact future performance. Overall, the company remains focused on growth and operational integration.

Simulations Plus beats earnings expectations, eyes TAM expansion opportunities

Simulations Plus delivered strong financial results, exceeding revenue and EPS expectations. While facing challenges in meeting organic growth targets, the company's strategic investments and acquisitions position it well for future growth. With a focus on expanding TAM and maintaining profitability, Simulations Plus remains optimistic about its prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. The Software segment offers software products for pharmaceutical research, development, and commercialization of the firm's products. The Services segment focuses on contracted consulting studies for customers and offers services supporting marketplace insight and medical communications for clinical and commercial drug development. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced that it has partnered with a large pharmaceutical company to validate the AIDD Module in ADMET Predictor 10.0 (APX).

Simulations Plus Partners with Large Pharmaceutical Company to Validate AI-Driven Drug Design Capabilities in ADMET Predictor®

LANCASTER, Calif--(BUSINESS WIRE)--Simulations Plus today announced the release of ADMET Predictor 10.0 (APX) - a major upgrade with new AI-Driven Drug Design & Transporters Modules.

Simulations Plus Releases ADMET Predictor® Version 10.0 (APX)

Schrodinger 

Veeva Systems

Three great performing yet relatively unknown med-tech stocks with a high upside.

Wildcard: Three Med-Tech Stocks to Watch

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced that chief executive officer Shawn O'Connor will present at LD Micro's LD 500 Virtual Conference on Sept.

Simulations Plus to Present at the LD 500 Virtual Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the closing of its public offering and the full exercise of the underwriters’ option to purchase additional shares.

Simulations Plus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the entry into an underwriting agreement for the sale of 1,818,182 shares of its common stock priced at $55 per share

Simulations Plus Announces Pricing of $100 Million Underwritten Offering of Common Stock

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.

Simulations Plus Announces Proposed Underwritten Public Offering

Simulation Plus: One-Of-A-Kind Bioinformatics Co. With A 20% 3-Year CAGR

Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q3 2020 Results - Earnings Call Transcript

Diversified Healthcare Trust

Hudson Pacific Properties

Shares of these businesses are making big moves in response to upcoming index changes. Here are the must-know details.

Why Diversified Healthcare Trust, Simulation Plus, and Hudson Pacific Properties Are Rising Today

HealthEquity

Q2 Hld

The Oracle of Omaha can't touch these high-growth businesses, but you can.

3 Stocks Warren Buffett Wishes He Could Buy

Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q2 2020 Results - Earnings Call Transcript

Simulations Plus (SLP) delivered earnings and revenue surprises of -14.29% and 6.92%, respectively, for the quarter ended February 2020. Do the numbers hold clues to what lies ahead for the stock?

Simulations Plus (SLP) Lags Q2 Earnings Estimates

Simulations Plus' (SLP) new COVID-19 focused offering is expected to drive the top line and give it a competitive edge in simulations software market.

Simulations Plus (SLP) Launches Program to Fight Coronavirus

California-based Simulations Plus (NASDAQ:SLP) develops modeling and simulation software primarily for use in pharmaceutical and biotechnology research.

Simulations Plus: A Pick-and-shovel Niche to Play the Speculative Drug Discovery Space

Accelerate Diagnostics

Two of the sector's biggest winners of the past 10 years are still flying under the radar. Which looks like the better buy today?

2 Growing Healthcare Stocks You Should Know

Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q1 2020 Results - Earnings Call Transcript

ABIOMED

ACADIA Pharma

DexCom

Exact Sciences

Jazz Pharmaceuticals

Neurocrine Biosciences

NeoGenomics

Repligen

The 10 Best Healthcare Stocks of the Decade

Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Simulations Plus (SLP) Earnings Expected to Grow: Should You Buy?

Simulations Plus: Fantastic Total Return With 65% Increase In Price Year To Date

Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q4 2019 Results - Earnings Call Transcript

Simulations Plus (SLP) delivered earnings and revenue surprises of 22.22% and 6.80%, respectively, for the quarter ended August 2019. Do the numbers hold clues to what lies ahead for the stock?

Simulations Plus (SLP) Beats Q4 Earnings and Revenue Estimates

Simulations Plus (SLP) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Simulations Plus has been struggling lately, but the selling pressure may be coming to an end soon.

Simulations Plus Sees Hammer Chart Pattern: Time to Buy?

Is  (SLP) Outperforming Other Computer and Technology Stocks This Year?

News for Simulations Plus Stock (SLP)